Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
13F holders, Q3 2023
Institutional positions in Verona Pharma plc as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- −3 vs. Q2 2023
- Shares held
- 65.3M
- +2.39M (+3.8%) vs. Q2 2023
- Total value
- $1.07B
- −$266.3M (−20.0%) vs. Q2 2023
- New holders
- 10
- 36 more added
- Sold out
- 13
- 33 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $359.0K |
| Q3 2025 | 243 | $8.57B |
| Q2 2025 | 292 | $7.18B |
| Q1 2025 | 258 | $4.58B |
| Q4 2024 | 191 | $3.19B |
| Q3 2024 | 150 | $1.95B |
| Q2 2024 | 125 | $957.0M |
| Q1 2024 | 113 | $1.08B |
| Q4 2023 | 117 | $1.35B |
| Q3 2023 | 102 | $1.07B |
| Q2 2023 | 105 | $1.33B |
| Q1 2023 | 95 | $1.21B |
| Q4 2022 | 88 | $1.31B |
| Q3 2022 | 68 | $529.0M |
| Q2 2022 | 40 | $145.9M |
| Q1 2022 | 39 | $181.7M |
| Q4 2021 | 42 | $248.0M |
| Q3 2021 | 40 | $202.7M |
| Q2 2021 | 37 | $239.9M |
| Q1 2021 | 37 | $305.1M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Verona Pharma plc; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,317,990 | $103.0M | 2.03% | 00.0% | Unchanged |
| FMR LLC | 6,957,958 | $113.4M | 0.01% | −151,812−2.1% | Reduced |
| Ally Bridge Group (NY) LLC | 0 | $0 | 0.00% | −487,631−100.0% | Sold out |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −381,939−100.0% | Sold out |
| HAP Trading, LLC | 0 | $0 | 0.00% | −43,805−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −37,136−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −29,432−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −21,700−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −14,008−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −11,960−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −11,591−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,910−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Tucker Asset Management LLC | 0 | $0 | 0.00% | −372−100.0% | Sold out |
| Impact Partnership Wealth, LLC | 0 | $0 | 0.00% | −99−100.0% | Sold out |